Discover and read the best of Twitter Threads about #solanezumab
Most recents (1)
1/n Good point, Mike. I can use #solanezumab as a case study in selective reporting of RCT trial results which does not serve patient’s interests. Sola was discontinued despite pooled results from 2 ph-3 trials suggesting that ‘mild’ (but not ‘moderate’) stage #Alzheimer patients
2/n may benefit. But a 3rd ph-3 trial in only ‘mild’ AD was clearly negative. Presumed reason was that the Rx did not lower brain amyloid levels enough. Lilly published the MRI findings from these studies looking at brain volume changes. They considered these results important to
3/n report because they noted that “Rates of whole brain volume & ventricular volume changes are sensitive markers of neurodegeneration & used as biomarker outcome measures in trials of potential disease‐modifying therapies.” tinyurl.com/33a7dkh3 They also reported on the
